Wednesday, May 08, 2013 10:42:17 AM
*had mid cycle review with the FDA regarding Otrexup and are confident of its success in achieving the advertised PDUFA date in October.
*exhibiting "highly controlled spending" as they ramp up for Otrexup launch
*First user study has been completed for QS T - similar path as Otrexup.
*in position to "DOMINATE the subcutaneous space" with the Vibex technology combination products platform. I really liked this statement!
*QS M (Neurologic) - intellectual property is being worked on and once all this is in place, the drug will be announced.
Otherwise, the main focus was on their injector platform, everything else is ancillary and not surprising, at least to me, as they have been clearly broadcasting this directive for some time now.
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM